person · Reporting owner
BIENAIME JEAN JACQUES
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ascendis Pharma A/SASND · Entity 1628 | Director | April 14, 2026 | September 28, 2026 |
| IMMUNIC, INC.VTL · Entity 6306 | Director | September 24, 2018 | September 24, 2018 |
| INCYTE CORPINCY · Entity 3182 | Director | June 08, 2026 | June 10, 2026 |
| Immunome Inc.IMNM · Entity 4219 | Director | June 10, 2026 | June 12, 2026 |
| Keros Therapeutics, Inc.KROS · Entity 6242 | Director | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ascendis Pharma A/S
Report date April 14, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $172.35 · Expires 2035-06-10 | Direct | 0 |
Reported balance
After 2026-04-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-14 · Disposition to issuer · Disposed 9,160 · Balance 0 F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. F1: The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $249.84 · Expires 2036-04-14 | Direct | 9,160 |
Reported balance
After 2026-04-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-14 · Grant · Acquired 9,160 · Balance 9,160 F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. F3: The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments.
F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer.
F3: The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments.
IMMUNIC, INC.
Report date September 24, 2018 · Filed September 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,500 |
Reported balance
After 2018-09-24 transaction · row 1
1 source rowRow 1 · 2018-09-24 · Sale · Disposed 26,619 · Balance 18,500 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.30 to $0.3021. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.30 to $0.3021. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.
INCYTE CORP
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,424 |
Reported balance
After 2026-06-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 1,642 · Balance 24,424 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
| Non Qualfied Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.64 · Expires 2036-06-07 | Direct | 6,111 |
Reported balance
After 2026-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-08 · Grant · Acquired 6,111 · Balance 6,111 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). |
Filing footnotes · ownership attribution and instrument terms
F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).
Immunome Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.16 · Expires 2036-06-09 | Direct | 9,897 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 9,897 · Balance 9,897 F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.
Keros Therapeutics, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,592 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Purchase · Acquired 1,000 · Balance 19,592 F1: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOMARIN PHARMACEUTICAL INC
Report date May 20, 2024 · Filed May 21, 2024
Section 16 reporting ended · disclosed 2024-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 473,792 |
Reported balance
After 2024-05-20 transaction · row 1
1 source rowRow 1 · 2024-05-20 · Tax withholding · Disposed 1,202 · Balance 473,792 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Jean-Jacques Bienaime Family Trust | 247,333 |
Reported balance
Holding disclosure · report date 2024-05-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 247,333 |
| Common StockSEC Table I · non-derivative | IndirectShares held as UTMA custodian for child 1 | 100 |
Reported balance
Holding disclosure · report date 2024-05-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 100 |
| Common StockSEC Table I · non-derivative | IndirectShares held as UTMA custodian for child 2 | 100 |
Reported balance
Holding disclosure · report date 2024-05-20 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 100 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 08, 2018 Filed Nov 9, 2018 21:21 UTC | INCYTE CORP INCY · Entity 3182 | PurchaseCommon Stock | 500 | $68.62 | $34,310.00 |
DisclosureSEC source: 0001209191-18-057953 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,168 Read SEC document |
| November 02, 2018 Filed Nov 5, 2018 22:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,500 | $0.00 Strike: $17.86 | $0.00 |
DisclosureSEC source: 0001567619-18-005098 · doc1.xml · derivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 1,500 shares Expires 2018-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 21, 2018. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| November 02, 2018 Filed Nov 5, 2018 22:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,500 | $97.88 | $146,820.00 |
DisclosureSEC source: 0001567619-18-005098 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,290 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 21, 2018. Read SEC document |
| November 02, 2018 Filed Nov 5, 2018 22:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,500 | $17.86 | $26,790.00 |
DisclosureSEC source: 0001567619-18-005098 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 21, 2018. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 21:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 4,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-18-005030 · doc1.xml · derivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,000 Underlying: Common Stock · 4,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 21:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 4,000 | $92.55 | $370,200.00 |
DisclosureSEC source: 0001567619-18-005030 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,290 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 21:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 4,000 | $14.39 | $57,560.00 |
DisclosureSEC source: 0001567619-18-005030 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 23:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-18-004953 · doc1.xml · derivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,000 Underlying: Common Stock · 1,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 23:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,000 | $14.39 | $14,390.00 |
DisclosureSEC source: 0001567619-18-004953 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 22:08 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-18-004648 · doc1.xml · derivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,000 Underlying: Common Stock · 1,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 22:08 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,000 | $14.39 | $14,390.00 |
DisclosureSEC source: 0001567619-18-004648 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 21:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,500 | $0.00 Strike: $17.86 | $0.00 |
DisclosureSEC source: 0001567619-18-003778 · doc1.xml · derivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 1,500 shares Expires 2018-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 21, 2018. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 21:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,500 | $99.36 | $149,040.00 |
DisclosureSEC source: 0001567619-18-003778 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,290 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 21, 2018. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 21:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,500 | $17.86 | $26,790.00 |
DisclosureSEC source: 0001567619-18-003778 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 21, 2018. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:11 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 209 | $69.08 | $14,437.72 |
DisclosureSEC source: 0001209191-18-053090 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,668 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 17:58 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-18-003172 · doc1.xml · derivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 1,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 17:58 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,000 | $14.39 | $14,390.00 |
DisclosureSEC source: 0001567619-18-003172 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2018 Filed Sep 24, 2018 23:24 UTC | IMMUNIC, INC. VTL · Entity 6306 | SaleCommon Stock | 26,619 | $0.30 | $8,001.67 |
DisclosureSEC source: 0001280776-18-000093 · wf-form4_153783147353536.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.30 to $0.3021. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4. Read SEC document |
| September 13, 2018 Filed Sep 18, 2018 01:24 UTC | IMMUNIC, INC. VTL · Entity 6306 | SaleCommon Stock | 20,000 | $0.47 | $9,400.00 |
DisclosureSEC source: 0001280776-18-000087 · wf-form4_153723383634954.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,119 Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,500 | $0.00 Strike: $17.86 | $0.00 |
DisclosureSEC source: 0001567619-18-002210 · doc1.xml · derivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 1,500 shares Expires 2018-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 21, 2018. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,500 | $98.16 | $147,240.00 |
DisclosureSEC source: 0001567619-18-002210 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,290 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 21, 2018. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,500 | $17.86 | $26,790.00 |
DisclosureSEC source: 0001567619-18-002210 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 21, 2018. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 23:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,500 | $0.00 Strike: $17.86 | $0.00 |
DisclosureSEC source: 0001140361-18-033548 · doc1.xml · derivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 1,500 shares Expires 2018-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 21, 2018. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 23:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,500 | $101.69 | $152,535.00 |
DisclosureSEC source: 0001140361-18-033548 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,290 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 21, 2018. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 23:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,500 | $17.86 | $26,790.00 |
DisclosureSEC source: 0001140361-18-033548 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 21, 2018. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:08 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 216 | $67.00 | $14,472.00 |
DisclosureSEC source: 0001209191-18-040951 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,459 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 23:53 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001140361-18-028678 · doc1.xml · derivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,000 Underlying: Common Stock · 1,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 23:53 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,000 | $14.39 | $14,390.00 |
DisclosureSEC source: 0001140361-18-028678 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 23:49 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 6,310 | $92.07 | $580,961.70 |
DisclosureSEC source: 0001140361-18-027597 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,290 Read SEC document |
| May 23, 2018 Filed May 25, 2018 20:09 UTC | IMMUNIC, INC. VTL · Entity 6306 | GrantStock Option (right to buy) · Derivative | 29,538 | $0.00 Strike: $6.10 | $0.00 |
DisclosureSEC source: 0001280776-18-000042 · wf-form4_152727892665112.xml · derivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,538 Underlying: Common Stock · 29,538 shares Expires 2028-05-22 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders. Read SEC document |
| May 17, 2018 Filed May 18, 2018 22:15 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 18,750 | $0.00 Strike: $38.59 | $0.00 |
DisclosureSEC source: 0001140361-18-024746 · doc1.xml · derivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,750 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 17, 2018 Filed May 18, 2018 22:15 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 18,750 | $88.66 | $1,662,356.25 |
DisclosureSEC source: 0001140361-18-024746 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,600 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $88.37 to $89.16. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 17, 2018 Filed May 18, 2018 22:15 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 18,750 | $38.59 | $723,562.50 |
DisclosureSEC source: 0001140361-18-024746 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. Read SEC document |
| May 16, 2018 Filed May 18, 2018 00:03 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 18,750 | $0.00 Strike: $38.59 | $0.00 |
DisclosureSEC source: 0001140361-18-024513 · doc1.xml · derivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 16, 2018 Filed May 18, 2018 00:03 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 18,750 | $89.13 | $1,671,131.25 |
DisclosureSEC source: 0001140361-18-024513 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,600 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $88.625 to $89.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 16, 2018 Filed May 18, 2018 00:03 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 18,750 | $38.59 | $723,562.50 |
DisclosureSEC source: 0001140361-18-024513 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. Read SEC document |
| May 15, 2018 Filed May 16, 2018 22:30 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 18,750 | $0.00 Strike: $38.59 | $0.00 |
DisclosureSEC source: 0001140361-18-024278 · doc1.xml · derivative · entry 7 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 18,750 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 15, 2018 Filed May 16, 2018 22:30 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 18,750 | $88.29 | $1,655,433.75 |
DisclosureSEC source: 0001140361-18-024278 · doc1.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,600 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. F3 · price: The price in column 4 is the weighted average price. The price actually received ranged from $87.65 to $88.70. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 15, 2018 Filed May 16, 2018 22:30 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 18,750 | $38.59 | $723,562.50 |
DisclosureSEC source: 0001140361-18-024278 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. Read SEC document |
| May 14, 2018 Filed May 16, 2018 22:30 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 18,750 | $0.00 Strike: $38.59 | $0.00 |
DisclosureSEC source: 0001140361-18-024278 · doc1.xml · derivative · entry 6 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 18,750 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 14, 2018 Filed May 16, 2018 22:30 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 18,750 | $89.22 | $1,672,850.63 |
DisclosureSEC source: 0001140361-18-024278 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,600 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $88.406 to $89.84. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 14, 2018 Filed May 16, 2018 22:30 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 18,750 | $38.59 | $723,562.50 |
DisclosureSEC source: 0001140361-18-024278 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. Read SEC document |
| May 11, 2018 Filed May 15, 2018 01:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 18,750 | $0.00 Strike: $38.59 | $0.00 |
DisclosureSEC source: 0001140361-18-023474 · doc1.xml · derivative · entry 8 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 18,750 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. F6 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 11, 2018 Filed May 15, 2018 01:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 18,750 | $88.42 | $1,657,856.25 |
DisclosureSEC source: 0001140361-18-023474 · doc1.xml · nonDerivative · entry 5 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,600 F3 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. F5 · price: The price in column 4 is the weighted average price. The price actually received ranged from $87.75 to $89.60. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 11, 2018 Filed May 15, 2018 01:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 18,750 | $38.59 | $723,562.50 |
DisclosureSEC source: 0001140361-18-023474 · doc1.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. Read SEC document |
| May 10, 2018 Filed May 15, 2018 01:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 18,750 | $0.00 Strike: $38.59 | $0.00 |
DisclosureSEC source: 0001140361-18-023474 · doc1.xml · derivative · entry 7 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 18,750 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. F6 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 10, 2018 Filed May 15, 2018 01:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 18,750 | $89.59 | $1,679,793.75 |
DisclosureSEC source: 0001140361-18-023474 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,600 F3 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. F4 · price: The price in column 4 is the weighted average price. The price actually received ranged from $89.055 to $90.170. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 10, 2018 Filed May 15, 2018 01:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 18,750 | $38.59 | $723,562.50 |
DisclosureSEC source: 0001140361-18-023474 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017. Read SEC document |
| May 01, 2018 Filed May 3, 2018 21:17 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $60.85 | $0.00 |
DisclosureSEC source: 0001209191-18-027713 · doc4.xml · derivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in option plan). Read SEC document |
| May 01, 2018 Filed Feb 13, 2019 23:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 160 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-003861 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Jean-Jacques Bienaime Family Trust Disclosed balance after: 181,341 F1 · date: On May 1, 2018 the reporting person gifted 160 shares to an educational institution. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.